Regenerative Medicine Manufacturing Society (RMMS) is partnering with STEM CELLS Translational Medicine to build a freely accessible collection of shared resources across three areas: models; cell therapies; and technologies. These resources will bring together the scientific community and highlight how the field of regenerative medicine is uniquely positioned to fight the COVID-19 pandemic.
Featured Articles - September 22, 2020
Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respiratory distress syndrome
Wenchun Qu, et al., STEM CELLS Translational Medicine
The potential benefits of mesenchymal stromal cell (MSC) therapy for patients with COVID‐19 acute respiratory distress syndrome support the rapid commencement of clinical trials, as well as the compassionate use of MSCs that already have documented safety profiles from FDA‐approved studies.
Ubiquitous overexpression of CXCL12 confers radiation protection and enhances mobilization of hematopoietic stem and progenitor cells
Smrithi Rajendiran, et al., STEM CELLS
The novel, inducible C‐X‐C motif chemokine ligand 12 (CXCL12) overexpression mouse model enables in‐depth mechanistic interrogation of CXCL12 function in development and disease. This study demonstrated that CXCL12 influences trafficking, proliferation, and radioresistance of hematopoietic stem cells and progenitors using this model. These findings are important for understanding hematopoietic development, cancer, and transplantation therapies.
An optimized protocol employing a vertical‐wheel bioreactor achieves the rapid generation of clinically-relevant numbers of human induced pluripotent stem cells
The neurotransmitter norepinephrine functions as a regulator of adult neural progenitor cell proliferation within the periventricular regions of the adult mouse brain
The modulation of B cell responses by mesenchymal stem cell therapy can blunt inflammatory responses in the lung and reduce progression to fibrosis